Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Neutral

MacroGenics, Inc. (MGNX)

Pharmaceutical Preparations

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

9704 MEDICAL CENTER DRIVE
Rockville, MD

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/10/2013

Market Cap

202,592,706

Shares Outstanding

62,030,000

Weighted SO

62,029,447

Total Employees

N/A

Upcoming Earnings

N/A

Beta

2.0740

Last Div

0.0000

Range

3.14-21.88

Chg

-0.0300

Avg Vol

1422462

Mkt Cap

202592706

Exch

NASDAQ

Country

US

Phone

301 251 5172

DCF Diff

4.3554

DCF

-0.0132

Div Yield

0.0000

P/S

4.9391

EV Multiple

-0.7986

P/FV

3.5006

Div Yield %

0.0000

P/E

-1.4842

PEG

-0.0806

Payout

-0.0004

Current Ratio

2.7104

Quick Ratio

2.6912

Cash Ratio

1.4495

DSO

55.0908

DIO

37.8969

Op Cycle

92.9877

DPO

177.9626

CCC

-84.9748

Gross Margin

0.7382

Op Margin

-4.7976

Pretax Margin

-3.3247

Net Margin

-3.3247

Eff Tax Rate

-0.0224

ROA

-0.6780

ROE

-1.0684

ROCE

-1.3739

NI/EBT

1.0000

EBT/EBIT

0.6930

EBIT/Rev

-4.7976

Debt Ratio

0.1693

D/E

0.5890

LT Debt/Cap

0.3390

Total Debt/Cap

0.3707

Int Coverage

113.5528

CF/Debt

-4.5045

Equity Multi

3.4787

Rec Turnover

6.6254

Pay Turnover

2.0510

Inv Turnover

9.6314

FA Turnover

0.9539

Asset Turnover

0.2039

OCF/Share

-2.4482

FCF/Share

-2.5058

Cash/Share

2.2401

OCF/Sales

-3.7401

FCF/OCF

1.0236

CF Coverage

-4.5045

ST Coverage

-34.8187

CapEx Coverage

-42.4608

Div&CapEx Cov

-41.7786

P/BV

3.5006

P/B

3.5006

P/S

4.9391

P/E

-1.4842

P/FCF

-1.2902

P/OCF

-1.3194

P/CF

-1.3194

PEG

-0.0806

P/S

4.9391

EV Multiple

-0.7986

P/FV

3.5006

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Sep 21, 20:59 Hagens Berman Reminds MacroGenics (MGNX) Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of Sept. 24, 2024 GlobeNewswire Inc. Sep 15, 20:04 MacroGenics (MGNX) Investors Alerted to September 24th Deadline in Securities Class Action, Encouraged to Contact Hagens Berman GlobeNewswire Inc. Sep 10, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CAE, MacroGenics, Vicor, and American Airlines and Encourages Investors to Contact the Firm GlobeNewswire Inc. Sep 08, 21:18 ROSEN, LEADING INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX GlobeNewswire Inc. Aug 27, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics, CrowdStrike, Vicor, and American Airlines and Encourages Investors to Contact the Firm GlobeNewswire Inc. Aug 26, 23:56 ROSEN, LEADING INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX GlobeNewswire Inc. Aug 25, 14:13 MacroGenics, Inc. (MGNX) Investors: September 24, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc. Aug 23, 21:37 MGNX INVETOR ALERT: Kirby McInerney LLP Reminds MacroGenics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit GlobeNewswire Inc. Aug 18, 16:20 TOP RANKED ROSEN LAW FIRM Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX GlobeNewswire Inc. Aug 17, 19:29 Kessler Topaz Meltzer & Check, LLP Encourages MacroGenics, Inc. Investors with Losses to Contact the Firm GlobeNewswire Inc. Aug 15, 00:13 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX GlobeNewswire Inc. Aug 11, 18:00 MGNX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! GlobeNewswire Inc. Aug 07, 21:46 Kirby McInerney LLP Reminds MacroGenics, Inc. (MGNX) Investors of Class Action Filing and Encourages Investors to Contact the Firm GlobeNewswire Inc. Aug 07, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vicor, American Airlines, and MacroGenics and Encourages Investors to Contact the Firm GlobeNewswire Inc. Aug 03, 20:39 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX GlobeNewswire Inc. Aug 03, 15:58 SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX GlobeNewswire Inc. Aug 01, 02:53 MACROGENICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MacroGenics, Inc. - MGNX GlobeNewswire Inc. Jan 08, 16:30 MacroGenics to Participate in Upcoming Investor Conference The Motley Fool Nov 07, 01:15 MacroGenics (MGNX) Q3 2023 Earnings Call Transcript The Motley Fool Nov 07, 01:15 MacroGenics (MGNX) Q3 2023 Earnings Call Transcript

Revenue Product Segmentation